Great. Thanks, Shai. I'll review highlights of our Q3 results and provide our expectations for the fourth quarter and the full year and then we'll take some questions. It was a strong quarter across the board with excellent loss ratio improvement coupled with rigorous cost control, resulting in strong results exceeding our own expectations. In-Force Premium or IFP grew 18% in Q3 as compared to the prior year to $719 million. As a reminder, the third quarter is the first quarter where our year-on-year comparisons include Metromile impact in both the current and the prior year results as the acquisition closed in July of 2022. Customer count increased by 12% to just shy of $2 million as compared to the prior year, premium per customer increased 6% versus prior year to $362 driven in roughly equal parts by rate increases and mix shift to higher priced products. Annual Dollar Retention or ADR was 85%. We measure ADR on an annual cohort basis and include the impact of changes in policy value, additional policy purchases and churn. There was some modest downward pressure on ADR this quarter from the addition of former Metromile customers in the current quarter metric calculation for the first time. Gross earned premium in Q3 increased 27%, as compared to the prior year to $173 million a bit faster than IFP growth, due to the partial quarter impact of Metromile results in Q3 of 2022. Revenue in Q3 increased 55% from the prior year to $115 million. The growth in revenue was driven by the increase in Gross Earned Premium as well as a 169% increase in investment income and a decline in the proportion of premium ceded to reinsurers. Our gross loss ratio was 83% for Q3, as compared to 94% in both Q3, 2022 and in Q2 of 2023. The impact of CATs in aggregate in Q3 was roughly 10% points within the gross loss ratio. About equal to the average quarterly CAT impact over the last couple of years, absent the total CAT impact the underlying gross loss ratio ex-CAT, with in line with the prior quarter and nearly 15% points better than the prior year. Prior period development was roughly 3.8% favorable impact in the quarter primarily due to pet [ph] reserve adjustments. Operating expenses excluding loss and loss adjustment expense decreased a 11% to $98 million in Q3, as compared to the prior year. A bit of detail on the unique entries in the quarter both one-off expenses related to the Metromile acquisition. We had a notable non-recurring expense in the quarter related to a successful sublet of excess office space in San Francisco, a lease acquired in conjunction with the Metromile acquisition. I'd consider the sublease of the space as a positive outcome in a very difficult West Coast real estate market. The current prevailing rents are well below the market peak of 2019 and as a result we have written down approximately $3.7 million in the quarter in relation to this transaction. We've also reserve $3 million for other potential liabilities related to Metromile operations pre-acquisition based on facts known now that were not apparent at the time of the acquisition. These expenses are included in G&A expense they impact our net operating loss, and earnings per share and have been excluded from our adjusted EBITDA calculation. Given the unique nature in relation to activities pre-acquisition. The San Francisco office lease was our only material excess real estate obligation. We're comfortable with our other existing lease obligations relative to our space needs in all of our physical locations. Other insurance expense grew 25% in Q3 versus the prior year, a bit ahead of the growth of earned premium primarily in support of our aggressive investments in our rate filing capacity. Total sales and marketing expense declined by $11 million or 32% primarily due to lower growth acquisition spending to acquire new customers. Total growth spend in the quarter was $12.6 million, down from $23 million in the prior year quarter. Growth spend was about 15% more efficient in Q3 versus a year ago, in part due to lower absolute spend, but also due to better results in certain marketing channels. In July, we began to draw down on our loan facility. Our synthetic agents program and financed about 50% of our Q3 growth spend. As a reminder, you'll see a 100% of our growth spend flow through the P&L as always. While the impact of the new financing mechanism, is visible on the cash flow statement in the balance sheet. Technology development expense increased just 2% close to flat versus the prior year. G&A expense decreased 9% as compared to the prior year. Personnel expense and headcount, continued to be quite stable despite continued growth in customers and premium, total head count is actually down about 5%, as compared to the prior year at 1,304. Net loss was $62 million in Q3 or a loss of $0.88 per share as compared to the $91 million loss we reported in the third quarter of 2022 or a loss of $1.37 per share. While adjusted EBITDA loss was $40 million in Q3, as compared to $66 million of adjusted EBITDA loss in the third quarter of 2022. Our total cash, cash equivalents and investments, ended the quarter at approximately $945 million, reflecting primarily a use of cash for operations of $103 million since year end 2022, and worth noting that that total cash and equivalents and investments balance was essentially unchanged versus the prior quarter. With these goals and metrics in mind, I'll outline our specific financial expectations for the fourth quarter and the full year. For the fourth quarter we expect in-force premium at December 31, between $726 million and $729 million. Gross earned premium between $174 million and $176 million. Revenue between $107 million and $109 million and adjusted EBITDA loss between $44 million and $42 million. Stock-based compensation of approximately $16 million, CapEx of approximately $3 million and a weighted average share count of approximately 70 million shares. And for the full year this would result in in-Force premium again at $726 million to $729 million, Gross Earned Premium between $665 million $667 million, revenue between $421 million $423 million. Adjusted EBITDA loss between $188 million and $186 million. Stock-based compensation of approximately $62 million, capital expenditures of approximately $10 million and again weighted average share count for the full year of approximately 70 million shares. All in all, a really strong quarter. It's worth summarizing the main headlines, cash flow positive expected by year end 2025. Adjusted EBITDA positive following by year end 2026. Continued progress on loss ratio, rate filings and approvals earning in with more to come. Impressive efficiency and nearly flat headcount. We can look back to almost two years ago when we first spoke about our expected peak loss quarter happening in Q3, 2022. Now a year out from that date, not only was that quarter indeed our peak loss quarter, but just one year later, our adjusted EBITDA loss has shrunk by nearly 40%. Taken together, our results give us confidence that we are on the path to creating a sizable, defensible and profitable business and we hope you see them similarly. With that, I'd like to hand things back over to Shai to answer some questions for our retail investors.